Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
AssigneeBristol-Myers Squibb Company
InventorArvin YANG
Life of this patent
Estimating the term…
Abstract
The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
Claims30
(canceled)
A method for treating a melanoma comprising administering to a patient afflicted with a melanoma tumor
- an anti-PD-1 antibody or an antigen-binding portion thereof that binds specifically to a human PD-1 (“anti-PD-1 antibody”) at a flat dose of 240 mg once every two weeks or 480 mg once every four weeks.
4-7. (canceled)
9-13. (canceled)
(canceled)
(canceled)
22-24. (canceled)
26-31. (canceled)
(canceled)
39-45. (canceled)
(canceled)
A method for treating a melanoma in a patient afflicted with a melanoma tumor, comprising administering to the patient nivolumab as a monotherapy at a flat dose of 240 mg once every two weeks or 480 mg once every four weeks, wherein the patient is identified as having a PD-L1-positive melanoma tumor prior to the administration.
Dependencies are inferred from the claim text.